Class | Name/Company | Approval Dates and Comments |
Actinic |
Hyal Pharmaceutical |
Approved in Canada, May 1998 for the topical treatment of |
Antibiotic |
Pfizer |
Recently approved by the FDA for 14 indications including |
Anti-HIV |
Glaxo Wellcome |
Approved by the EC Commision. Combivir aims to |
UV-induced |
Medicis Pharmaceutical |
Recently approved by the FDA for the treatment of photoinduced |
Antiviral Agent |
|
The US FDA issued an approvable letter in June 2000, for the treatment of oral facial herpes. Docosanol is the first approvable OTC treatment for this disease. |
Oncologic Agent |
Gensia Sicor Pharmaceuticals |
The US FDA tentatively approved Gensia Sicor Pharmaceuticals’ ANDA in June 2000, for the generic injection form of Bristol-Myers Squibb’s bleomycin (Blenoxane). If fully approved, bleomycin will be used alone or in combination with other chemotherapeutic agents for the management of squamous cell carcinoma, lymphomas and testicular carcinoma. |
New Developments | ||
Leprosy |
|
Approved in India, this vaccine is said to be the first to |
Scleroderma |
|
A preliminary report from workers in Boston suggests that |
New Side Effect | |
Protease |
Lumps, humps and bumps of mature pockets of adipose tissue have been described in patients |